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Fossil records date human use of plants as
medicines at least to the Middle Paleolithic
age some 60,000 years ago (1). From that
point the development of traditional medical
systems incorporating plants as a means of
therapy can be traced back only as far as
recorded documents of their likeness.
However, the value of these systems is much
more than a significant anthropologic or
archeologic fact. Their value is as a methodol-
ogy of medicinal agents, which, according to
the World Health Organization (WHO),
almost 65% of the world’s population have
incorporated into their primary modality of
health care (2). The goals of using plants as
sources of therapeutic agents are a) to isolate
bioactive compounds for direct use as drugs,
e.g., digoxin, digitoxin, morphine, reserpine,
taxol, vinblastine, vincristine; b) to produce
bioactive compounds of novel or known
structures as lead compounds for semisynthe-
sis to produce patentable entities of higher
activity and/or lower toxicity, e.g., met-
formin, nabilone, oxycodon (and other nar-
cotic analgesics), taxotere, teniposide,
verapamil, and amiodarone, which are based,
respectively, on galegine, ∆9-tetrahydro-
cannabinol, morphine, taxol, podophyllo-
toxin, khellin, and khellin; c) to use agents as
pharmacologic tools, e.g., lysergic acid diethy-
lamide, mescaline, yohimbine; and d) to use
the whole plant or part of it as a herbal rem-
edy, e.g., cranberry, echinacea, feverfew, gar-
lic, ginkgo biloba, St. John’s wort, saw
palmetto. In this review we consider the past,
present, and future value of employing infor-
mation from plants used in traditional med-
ical practices (ethnomedicine) for the
discovery of new bioactive compounds.
The number of higher plant species
(angiosperms and gymnosperms) on this
planet is estimated at 250,000 (3), with a
lower level at 215,000 (4,5) and an upper level
as high as 500,000 (6,7). Of these, only about
6% have been screened for biologic activity,
and a reported 15% have been evaluated
phytochemically (8). With high throughput
screening methods becoming more advanced
and available, these numbers will change, but
the primary discriminator in evaluating one
plant species versus another is the matter of
approach to finding leads. There are some
broad starting points to selecting and obtain-
ing plant material of potential therapeutic
interest. However, the goals of such an
endeavor are straightforward.
Plants have an advantage in this area
based on their long-term use by humans
(often hundreds or thousands of years). One
might expect any bioactive compounds
obtained from such plants to have low
human toxicity. Obviously, some of these
plants may be toxic within a given endemic
culture that has no reporting system to doc-
ument these effects. It is unlikely, however,
that acute toxic effects following the use of a
plant in these cultures would not be noticed,
and the plant would then be used cautiously
or not at all. Chronic toxic effects would be
less likely to signal that the plant should not
be used. In addition, chemical diversity of
secondary plant metabolites that results
from plant evolution may be equal or supe-
rior to that found in synthetic combinatorial
chemical libraries. 
It was estimated that in 1991 in the
United States, for every 10,000 pure com-
pounds (most likely those based on synthesis)
that are biologically evaluated (primarily
in vitro), 20 would be tested in animal mod-
els, and 10 of these would be clinically evalu-
ated, and only one would reach U.S. Food
and Drug Administration approval for mar-
keting. The time required for this process was
estimated as 10 years at a cost of $231 million
(U.S.) (9).
Most large pharmaceutical manufacturers
and some small biotechnology ﬁrms have the
ability to screen 1,000 or more substances per
week using high throughput in vitro assays. In
addition to synthetic compounds from their
own programs, some of these companies
screen plant, microbial, and marine organisms.
Thus, the challenges facing these compa-
nies in acquiring organisms and extracts (vide
infra) usually result in a failure to consider
collection of plants, especially if the acquisi-
tions are based on ethnomedical use. It is
time-consuming to collect speciﬁc plants hav-
ing an ethnomedical history. Despite these
problems, one cannot discount the past
importance of plants as sources of structurally
novel drugs (Tables 1 and 2).
Ethnomedicine may be deﬁned broadly as
the use of plants by humans as medicines
(10,11); but this use could be called more
accurately ethnobotanic medicine. Traditional
medicine is a broad term used to define any
non-Western medical practice (12). Ethno-
pharmacology is a highly diversiﬁed approach
to drug discovery involving the observation,
description, and experimental investigation of
indigenous drugs and their biologic activities.
It is based on botany, chemistry, biochem-
istry, pharmacology, and many other disci-
plines (anthropology, archaeology, history,
and linguistics) that contribute to the discov-
ery of natural products with biologic activity
(13). These three areas of endeavor will be the
starting point for this review. 
Approaches to Drug Discovery
Using Higher Plants
Several reviews pertaining to approaches for
selecting plants as candidates for drug discov-
ery programs have been published (8,14–27);
however, most concern screening plants for
anticancer or anti-HIV activity. We outline
these approaches brieﬂy before concentrating
on the ethnomedical approach, the major
topic of this review. Examples from the litera-
ture are intended to be representative but not
exhaustive.
Random selection followed by chemical
screening. These so-called phytochemical
screening approaches [i.e., for the presence of
cardenolides/bufadenolides, alkaloids, triter-
penes, flavonoids, isothiocyanates, iridoids,
etc. (17)] have been used in the past and are
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currently pursued mainly in the developing
countries. The tests are simple to perform,
but false-positive and false-negative tests often
render results difficult to assess (17,28–30).
More important, it is usually impossible to
relate one class of phytochemicals to speciﬁc
biologic targets; for example, the alkaloids or
flavonoids produce a vast array of biologic
effects that are usually not predictable in
advance.
Random selection followed by one or more
biologic assays. In the past, plant extracts were
evaluated mainly in experimental animals,
primarily mice and rats. The most extensive
of these programs were sponsored by the
National Cancer Institute (NCI) (24,31–34)
in the United States and the Central Drug
Research Institute (CDRI) in India (35–41).
More than 35,000 species were screened in
vitro and later in vivo at NCI from 1960 to
1981. Taxol and camptothecin (42) were dis-
covered in this program as well as several
other plant-derived compounds that were
unsuccessful in human studies. In 1986 the
NCI program abandoned this approach and
continued to collect and screen plants using a
battery of 60 human tumor cell lines and also
initiated a screening of plants for anti-HIV
activity in vitro. Calanolide A, currently in
Phase I clinical trials, was developed from this
program (43,44).
The CDRI evaluated approximately
2,000 plant species for several biologic activi-
ties, including antibacterial, antidiabetic,
antifertility, antifungal, antihypercholes-
teremic, anti-inflammatory, antitumor,
cardiovascular, central nervous-system depres-
sant, cytotoxicity, diuretic, and others (37).
To date no biologically active drugs for
human use have arisen from that program,
even though a large number of known and
novel bioactive compounds were isolated
from the active plants (45).
Follow-up of biologic activity reports.
These reports showed that the plant extracts
had interesting biologic activity, but the
extracts were not studied for their active prin-
ciples. The literature from the 1930s through
the 1970s contains these types of reports.
Follow-up of ethnomedical (traditional
medicine) uses of plants. Several types of
ethnomedical information are available:
Plants used in organized traditional
medical systems. Ayurveda, Unani, Kampo,
and traditional Chinese medicine have ﬂour-
ished as systems of medicine in use for thou-
sands of years. Their individual arrangements
all emphasize education based on an estab-
lished, frequently revised body of written
knowledge and theory. These systems are still
in place today because of their organizational
strengths, and they focus primarily on multi-
component mixtures (12). Even though
Western medical science views such systems
Table 1. Drugs derived from plants, with their ethnomedical correlations and sources. 
Drug Action or clinical use Plant source
Acetyldigoxin Cardiotonic Digitalis lanata Ehrh.
Adoniside Cardiotonic Adonis vernalis L.
Aescin Anti-inﬂammatory Aesculus hippocastanum L.
Aesculetin Antidysentery Fraxinus rhynchophylla Hance
Agrimophol Anthelmintic Agrimonia eupatoria L.
Ajmalicine Circulatory disorders Rauvolﬁa serpentina (L.) Benth ex. Kurz
Allyl isothiocyanate Rubefacient Brassica nigra (L.) Koch
Andrographolide Bacillary dysentery Andrographis paniculata Nees
Anisodamine Anticholinergic Anisodus tanguticus (Maxim.) Pascher
Anisodine Anticholinergic Anisodus tanguticus (Maxim.) Pascher
Arecoline Anthelmintic Areca catechu L.
Asiaticoside Vulnerary Centella asiatica (L.) Urban
Atropine Anticholinergic Atropa belladonna L.
Berberine Bacillary dysentery Berberis vulgaris L.
Bergenin Antitussive Ardisia japonica Bl.
Bromelain Anti-inﬂammatory; proteolytic agent Ananas comosus (L.) Merrill
Caffeine CNS stimulant Camellia sinensis (L.) Kuntze
(+)-Catechin Haemostatic Potentilla fragaroides L.
Chymopapain Proteolytic; mucolytic Carica papaya L.
Cocaine Local anaesthetic Erythroxylum coca Lamk.
Codeine Analgesic; antitussive Papaver somniferum L.
Colchicine Antitumor agent; antigout Colchicum autumnale L.
Convallotoxin Cardiotonic Convallaria majalis L.
Curcumin Choleretic Curcuma longa L.
Cynarin Choleretic Cynara scolymus L.
Danthron Laxative Cassia spp.
Deserpidine Antihypertensive; tranqulizer Rauvolﬁa canescens L.
Deslanoside Cardiotonic Digitalis lanata Ehrh.
Digitalin Cardiotonic Digitalis purpurea L.
Digitoxin Cardiotonic Digitalis purpurea L.
Digoxin Cardiotonic Digitalis lanata Ehrh.
Emetine Amoebicide; emetic Cephaelis ipecacuanha (Brotero) A. Richard
Ephedrine Sympathomimetic Ephedra sinica Stapf.
Etoposide Antitumour agent Podophyllum peltatum L.
Gitalin Cardiotonic Digitalis purpurea L.
Glaucaroubin Amoebicide Simarouba glauca DC.
Glycyrrhizin Sweetener Glycyrrhiza glabra L.
Gossypol Male contraceptive Gossypium spp.
Hemsleyadin Bacillary dysentery Helmsleya amabilis Diels
Hydrastine Hemostatic; astringent Hydrastis canadensis L.
Hyoscamine Anticholinergic Hyoscamus niger L.
Kainic Acid Ascaricide Digenea simplex (Wulf.) Agardh
Kawain Tranquilizer Piper methysicum Forst. f.
Khellin Bronchodilator Ammi visnaga (L.) Lamk.
Lanatosides A, B, C Cardiotonic Digitalis lanata Ehrh.
Lobeline Smoking deterrent; respiratory stimulant Lobelia inﬂata L.
Monocrotaline Antitumor agent Crotolaria sessiliﬂora L.
Morphine Analgesic Papaver somniferum L.
Neoandrographolide Bacillary dysentery Andrographis paniculata Nees
Noscapine Antitussive Papaver somniferum L.
Ouabain Cardiotonic Strophanthus gratus Baill.
Papain Proteolytic; mucolytic Carica papaya L.
Phyllodulcin Sweetener Hydrangea macrophylla (Thunb.) DC
Physostigmine Cholinesterase inhibitor Physostigma venenosum Balf.
Picrotoxin Analeptic Anamirta cocculus (L.) W.&A.
Pilocarpine Parasympathomimetic Pilocarpus jaborandi Holmes
Podophyllotoxin Condylomata acuminata Podophyllum peltatum L.
Protoveratrines A & B Antihypertensive Veratrum album L.
Pseudoephedrine Sympathomimetic Ephedra sinica Stapf.
Pseudoephedrine, nor- Sympathomimetic Ephedra sinica Stapf.
Quinine Antimalarial Cinchona ledgeriana Moens ex. Trimen
Quisqualic Acid Anthelmintic Quisqualis indica L.
Rescinnamine Antihypertensive; tranqulizer Rauvolﬁa serpentina (L.) Benth ex. Kurz
Reserpine Antihypertensive; tranqulizer Rauvolﬁa serpentina (L.) Benth ex. Kurz
Rhomitoxin Antihypertensive Rhododendron molle G. Don
Rorifone Antitussive Rorippa indica (L.) Hochr.
Rotenone Piscicide Lonchocarpus nicou (Aubl.) DC.
Rotundine Analgesic; sedative Stephania sinica Diels
Salicin Analgesic Salix alba L.
Santonin Ascaricide Artemisia maritima L.
(Continued)
109S1.Part 1  2/21/01 5:03 PM  Page 70    (Black plate)The value of plants used in traditional medicine for drug discovery
as lacking credibility, undeniably they are
used widely by most people on this planet.
Adverse effects from those widely used plants
are not well documented in the literature, and
efﬁcacy of these plants and plant mixtures is
more difﬁcult to assess by Western scientiﬁc
methods.
Herbalism, folklore, and shamanism.
These center on an apprenticeship system of
information passed to the next generation
through a shaman, curandero, traditional
healer, or herbalist. The plants that are used
are often kept secret by the practitioner, so lit-
tle information about them is recorded; thus
there is less dependence on scientiﬁc evidence
as in systems of traditional medicine that can
be subject to scrutiny. The shaman or herbal-
ist combines the roles of pharmacist and med-
ical doctor with the cultural/spiritual/religious
beliefs of a region or people, which are often
regarded as magic or mysticism. This
approach is widely practiced in Africa and
South America (45). 
Ethnomedical information can be
acquired from various sources such as books
on medical botany (46) and herbals (47);
review articles (usually involving surveys of
medicinal plants by geographic region or eth-
nic culture) (48–66); notes placed on voucher
herbarium specimens by the botanist at the
time of collection (67); ﬁeld work (68); and
computer databases, e.g., NAPRALERT
(69–71) and USDA–Duke (72,73).
Use of databases. The NAPRALERT data-
base (69–71) currently contains information
on 43,879 species of higher plants covering
ethnomedical, chemical, and pharmacologic
(including clinical studies) uses. Of these,
13,599 species contain ethnomedical data,
distributed among 3,607 genera and 273
plant families. Thus it is possible to correlate
ethnomedical use with experimental biochem-
ical or pharmacologic activities (in vitro, in
vivo, or in humans) to identify plants having
both types of activity for a given effect—e.g.,
anticancer, antidiabetic, antimalarial.
Other approaches. Our group was inter-
ested in identifying plants that could yield
intensely sweet compounds. In addition, we
searched the literature for Latin binomials
that would imply sweetness—e.g., saccharum,
dulcis, dulcificum, dulcifica, dulce, sacchartus,
saccharoides. (74). We actually tasted small
segments from leaves of 184 Stevia herbarium
specimens from the John G. Searle
Herbarium of the Field Museum of Natural
History in Chicago, Illinois. Of these, 18
species and varieties of Stevia had a sweet
taste, but none were sweeter than Stevia
rebaudiana, the source of stevioside, the
intensely sweet kaurene glycoside. (75).
The Value of Ethnomedicine 
A few examples document the value of using
ethnomedical information to initiate drug
discovery efforts. We were requested by the
WHO Traditional Medicine Programme
(TRM) several years ago to provide evidence
that ethnomedical information did indeed
lead to useful drug discovery. We sent letters
to the WHO–TRM centers throughout the
world asking for their assistance in identifying
all plant-derived pure compounds used as
drugs in their respective countries. In addi-
tion, we surveyed pharmacopoeias of devel-
oped and developing countries to identify all
such useful drugs. Next we surveyed the sci-
entific literature to find the original papers
reporting isolation of these compounds from
their respective plants. This was done to
determine whether the chemical efforts were
stimulated by ethnomedical claims and to
correlate current uses for the compounds with
such ethnomedical claims (2).
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Table 1. Continued.
Drug Action or clinical use Plant source
Scillarin A Cardiotonic Urginea maritima (L.) Baker
Scopolamine Sedative Datura metel L.
Sennosides A & B Laxative Cassia spp.
Silymarin Antihepatotoxic Silybum marianum (L.) Gaertn.
Stevioside Sweetener Stevia rebaudiana Bertoni
Strychnine CNS stimulant Strychnos nux-vomica L.
Teniposide Antitumor agent Podophyllum peltatum L.
Tetrahydropalmatine Analgesic; sedative Corydalis ambigua (Pallas) Cham. & Schltal.
Theobromine Diuretic; bronchodilator Theobroma cacao L.
Theophylline Diuretic; bronchodilator Camellia sinensis (L.) Kuntze
Trichosanthin Abortifacient Thymus vulgaris L.
Tubocurarine Skeletal muscle relaxant Chondodendron tomentosum R. & P.
Valepotriates Sedative Valeriana ofﬁcinalis L.
Vincamine Cerebral stimulant Vinca minor L.
Xanthotoxin Leukoderma; vitiligo Ammi majus L.
Yohimbine Aphrodisiac Pausinystalia yohimbe (K.Schum.) Pierre
Yuanhuacine Abortifacient Daphne genkwa Seib. & Zucc.
Yuanhuadine Abortifacient Daphne genkwa Seib. & Zucc.
Data adapted from Farnsworth et al. (2). 
Table 2. Plant-derived drugs and their sources not developed on the basis of ethnomedical information.
Drug Plant source
Allantoin Several plants
Anabasine Anabasis aphylla L.
Benzyl benzoate Several plants
Borneol Several plants
Camphor Cinnamonum camphora (L.) J.S. Presl
Camptothecin Camptotheca acuminata Decne.
Cissampeline Cissampelos pareira L.
Colchicaine amide Colchicum autumnale L.
Demecolcine Colchicum autumnale L.
L-Dopa Mucuna deeringiana (Bort) Merr.
Galanthamine Lycoris squamigera Maxim.
Glaucine Glaucium ﬂavum Crantz
Glaziovine Ocotea glazovii Mez
Hesperidin Citrus spp.
Huperzine A Huperzia serrata (Thunb. ex Murray) Trevis.
Menthol Mentha spp.
Methyl salicylate Gaultheria procumbens L.
Nicotine Nicotiana tabacum L.
Nordihydroguaiaretic acid Larrea divaricata Cav.
Pachycarpine Sophora pachycarpa Schrenk ex C.A. Meyer
Palmatine Coptis japonica Makino
Papaverine Papaver somniferum L.
Pinitol Several plants
Quinidine Cinchona ledgeriana Moens ex. Trimen
Rutin Citrus spp.
Sanguinarine Sanguinaria candensis L.
Sparteine Cytisus scoparius (L.) Link
Taxol Taxus brevifolia Nutt.
Tetrahydrocannabinol Cannabis sativa L.
Tetrandrine Stephania tetrandra S.Moore
Thymol Thymus vulgaris L.
Vasicine (peganine) Adhatoda vasica Nees
Vinblastine Catharanthus roseus (L.) G. Don
Vincristine Catharanthus roseus (L.) G. Don
Data adapted from Farnsworth et al. (2).
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A total of 122 compounds were identi-
ﬁed; 80% of these compounds were used for
the same (or related) ethnomedical purposes
(Table 1). Further, it was discovered that
these compounds were derived from only 94
species of plants (2).
Because these compounds are derived
from only 94 species of plants, and a conserv-
ative estimate of the number of flowering
plants occurring on the planet is 250,000,
there should be an abundance of drugs
remaining to be discovered in these plants.
The question is, what is the best approach to
discover plants that contain potential drugs? 
Several years ago we were visited by a
Mexican physician who presented us with
small pieces (30 g) of the roots of a Mexican
plant alleged to alleviate toothache pain. One
of us (NRF) placed a piece of the root in his
mouth and experienced a pronounced local
anesthetic effect lasting for about 60 min.
Before receiving a voucher specimen of the
plant for identification purposes, we made a
50% ethanol extract of the roots and evaluated
it in the acetic acid–induced writhing inhibi-
tion test in mice (i.g.). A subfraction, showing
one major spot following thin layer chro-
matography, gave an ED50 of 19.04 mg/kg
(i.g.). Morphine showed an ED50 of 2.0
mg/kg (i.g.). Within 2 days a pure compound
was isolated in high yield, identiﬁed and syn-
thesized within 1 week. The pure compound
was active in this assay, but 40% of the mice
died within 40 min of administration at a dose
of 40 mg/kg (i.g.). The ED50 of this com-
pound was 6.98 mg/kg (i.g.). The plant was
then identiﬁed as Heliopsis longipes (A. Gray)
Blake, and the isolated bioactive compound
was identified as the previously known
isobutylamide, afﬁnin (spilanthol) (76).
The investigation of this plant was initiated
by an ethnomedical report (76) of the use of
the plant as an analgesic (actually, a local anes-
thetic). With combined efforts of a pharma-
cognosist, chemist, pharmacologist, and
botanist, the bioactive constituent was identi-
ﬁed in less than 2 weeks.
In 1985 the WHO Special Programme of
Research and Training in Human
Reproduction embarked on a program called
“The Task Force on Plants for Fertility
Regulation” (77). The charge was to select
plants on the basis of ethnomedical claims
related to human reproduction, e.g., abortifa-
cient, contraceptive, ecbolic, emmenagogue.
Safety with long-term use was presumed. The
ultimate goal was to discover orally active,
pure substances that were nonestrogenic,
nonsteroidal, and nontoxic anti-implantation
agents. Work was to take place initially in
designated centers in the United States,
England, South Korea, Brazil, India, and
Hong Kong, with additional centers later
established in the People’s Republic of China
and Thailand. Our initial effort involved
searching all available literature for plants and
natural compounds having any of these bio-
logic effects and storing this information in
our NAPRALERT database for eventual
analysis (71). We were able to identify
approximately 4,000 plant species. A com-
puter analysis of the data produced about 300
species that were scheduled for collection and
testing. About 250 species were evaluated for
anti-implantation activity in rats (with conﬁr-
mation in hamsters) and approximately 50
were of sufficient interest to start chemical
isolation studies. Several active compounds
were identiﬁed, the most promising being an
indole alkaloid named yuehchukene (YCK)
(78) from the plant Murraya paniculata (L.)
Jack (Figure 1), used in China to regulate fer-
tility. Unfortunately, YCK showed a low level
of estrogenicity and was not further explored.
The WHO program was terminated shortly
thereafter.
Perhaps the first company in the United
States to investigate plants strictly through
the ethnomedical approach was Shaman
Pharmaceuticals in South San Francisco,
California. (79) Their approach was to send
botanist/physician teams to tropical areas to
assess firsthand the use of plants by tradi-
tional healers and to collect interesting plants
and assess them for validity in the Shaman
laboratories. Initial interest was directed
toward antifungal and antiviral agents (80);
several active compounds were discovered but
were either toxic or failed in the clinic. Efforts
were then directed toward antidiarrheal activ-
ity. SP-303, an oligomeric proanthocyanidin
(81), was shown to be clinically efficacious
and is currently marketed as a dietary supple-
ment for diarrhea. In addition, a major effort
was directed toward discovery of novel anti-
diabetic agents, which resulted in the discov-
ery of several patented compounds:
cryptolepine (82–84), maprouneacin (85),
3β,30-dihydroxylupen-20(29)-en-2-one (86),
harunganin (87), vismin (87), and quinones
SP18904 and SP18905 (88). The most inter-
esting discovery was nordihydroguaiaretic
acid (ndga) (89) (Figure 2) which, besides
being active orally in db/db diabetic mice,
also lowered cholesterol levels. In 1999
Shaman terminated their research in drug
discovery. 
In 1985 we proposed an approach,
based on ethnomedical information, to
experimentally pursue plants as a source of
Figure 1. Structure of yuehchukene.
Figure 2. Structure of nordihydroguaiaretic acid
(ndga).
N
Me
Me
Me
H
H
H
H
HO
H3CC H 3 HO
OH
OH
Figure 3. Flow chart of sequence for the study of plants used in traditional medicine. Adapted from Farnsworth et al. (2). 
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drugs. The approach was designed primarily
for implementation by developing coun-
tries, where lack of hard currency often pre-
vents sophisticated types of research from
being conducted. The possibility of drug
development in the form of stable, stan-
dardized crude extracts and eventual devel-
opment of the active principles from these
plants was envisioned (2) (Figure 3).
Some examples of drugs from plants that
served as models for the next generation of
drugs are exemplified as follows: Khellin
[from Ammi visnaga (L.) Lamk.] was used as
a bronchodilator in the United States until it
was shown to produce nausea and vomiting
after prolonged use. In 1955 a group of
chemists in England set about to synthesize
khellin analogs as potential bronchodilators
with fewer side effects. This eventually led to
the discovery of chromolyn (used as sodium
chromoglycate), which stabilized cell mem-
branes in the lungs to prevent the allergen-
induced release of the substance ultimately
causing bronchoconstriction in allergic
asthma patients (90). Further studies else-
where led to the synthesis of amiodarone, a
useful antiarrythmia agent (90). The struc-
tural relationship can be seen in Figure 4. 
Papaverine, useful as a smooth muscle
relaxant, provided the basic structure for vera-
pamil, a drug used to treat hypertension (90)
(Figure 5).
Galegine was isolated as an active anti-
hyperglycemic agent from the plant Galega
officinalis L. This plant was used ethnomed-
ically for the treatment of diabetes. Galegine
provided the template for the synthesis of
metformin and opened up interest in the syn-
thesis of other biguanidine-type antidiabetic
drugs (Figure 6) (90).
It is extremely difﬁcult to assess the value
of any approach to the use of higher plants to
develop new drugs. Artuso (91) has outlined
the entire process: formulating an appropriate
strategy, obtaining biologic extracts, screening
those extracts, isolating active compounds,
conducting preclinical tests and chemical
modification, submitting an Investigational
New Drug Application, performing clinical
trials, submitting a New Drug Application,
and beginning commercial production. He
estimates the entire process would take 10–20
years or more. Using complex mathematical
formulae, he discusses what the expected pay-
off would be relative to such variables as the
number of available plant species on earth,
the amount of biodiversity in the tropical rain
forests, and extinction rates. An element that
all estimated projections fail to consider is
that any of the 250,000 higher plant species
on earth could conceivably produce a new
drug, leaving all other criteria, projections,
and speculations aside. The reason is that the
introduction of novel mechanism-based in
vitro bioassays is virtually limitless, and there-
fore any plant, regardless of the extent of
prior biologic or chemical study, could prove
interesting as a potential new drug source.
For example, from 1960 to 1981 NCI col-
lected and screened approximately 35,000
plant species for anticancer activity (32).
Eventually, all residual extracts from these
35,000 species were destroyed after they were
assessed for anticancer activity. Thus, in spec-
ulating that about 6% of the 250,000 plant
species on earth have been evaluated as a
source of drugs (8), should one count the
35,000 species screened by NCI for anti-
cancer activity within the number of 6%? We
think not. Thus, because it is improbable that
one could collect all the 250,000 higher plant
species to screen for one or more biologic
activities, and because the number of bioas-
says that one could screen these species for is
unlimited, one must select judiciously those
species most likely to produce useful activity.
In addition, the biologic targets must repre-
sent the activities that correlate best with the
rationale for plant selection. It would appear
that selection of plants based on long-term
human use (ethnomedical) in conjunction
with appropriate biologic assays that correlate
with the ethnomedical uses would be most
appropriate.
There are advantages and disadvantages of
using plants as the starting point in any drug
development program. If one elects to use
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information suggesting that specific plants
may yield useful drugs based on long-term
use by humans (ethnomedicine) one can
rationalize that any isolated active com-
pounds from the plants are likely to be safer
than active compounds from plants with no
history of human use. Also, plants are a
renewable source of starting material in many
but not all cases. It is universally believed that
plants provide an unlimited source of novel
and complex chemical structures that most
likely would never be the subject of a begin-
ning synthetic program, e.g., vinblastine, vin-
cristine, taxol, d-tubocurarine, digoxin. If the
active principles derived from plants have
novel structures and useful biologic activity,
patent protection can be assured. We have
shown here that most useful drugs derived
from plants have been discovered by follow-
up of ethnomedical uses (Table 1). Further,
the trend today, especially in an industrial set-
ting, is to seek bioactive compounds from
plants that will serve as lead compounds for
synthetic or semisynthetic development, to
assure patent protection. Thus, this dimin-
ishes the need to isolate novel bioactive struc-
tures from plants, since the ultimate goal is to
use the active compounds to produce syn-
thetic derivatives with lower toxicity and
higher efﬁcacy.
Several pitfalls can emerge when deciding
to use plants, through either random selec-
tion or ethnomedical claims involving the
targeted disease. 
First, plants as biologic systems have
inherent potential variability in their chem-
istry and resulting biologic activity. In our
experience, perhaps 25% of all plants show-
ing promising biologic activity in our assay
systems fail to have the activity conﬁrmed on
subsequent re-collections. This could be due
to variability in the chemistry of plants or in
the bioassay systems used, or mix-ups in
labeling of plant samples or their taxonomic
identiﬁcations. We have previously discussed
and provided examples of these problems and
their solutions (17,18,21,29).
Second, the Convention on Biological
Diversity in 1992 expected the parties to the
convention to a) develop national biodiversity
protection plans and programs for sustainable
use; b) inventory and monitor components of
biologic diversity that are threatened, endan-
gered, or of economic, cultural, or scientific
value; c) establish a system of protected areas
with appropriate guidelines for their selection
and management; d)establish and maintain
facilities for ex situ conservation; e) establish
programs for scientiﬁc research and technical
training related to identification, conserva-
tion, and sustainable use of biological diver-
sity; and f ) integrate consideration of
conservation and sustainable use of biologic
resources into national decision making (92).
Since 1992, the countries with the most
biologic diversity—i.e., where tropical rain
forests predominate—have either prohibited
collection of plant material for export or
promulgated regulations that make it diffi-
cult to collect plant samples (or other bio-
logic specimens). Several issues are tied in
with the restrictions set forth by countries,
including preservation of genetic material,
intellectual property rights, and compensa-
tion for discoveries arising from their genetic
resources. These problems and potential
solutions have been discussed thoroughly
(92–97). We have found that in areas where
regulations permit plant collection and
export, at least 2 years are required to nego-
tiate and obtain permission to collect plant
materials.
Third, collecting plant samples randomly
in a speciﬁc geographic area can be done sim-
ply and rapidly. With a team of four to five
people, at least 200 samples of 0.5–1.0 kg
(dry weight) each can be collected daily.
However, collecting plants on the basis of
their ethnomedical claims requires consider-
able preliminary planning to determine
a) where each plant grows, b) what the abun-
dance of each plant is, c) whether any of the
plants are threatened or endangered, d) what
local arrangements must be made to collect
the plants, e.g. permits, and e) whether local
botanists familiar with the ﬂora of the region
are available to assist. Thus, the number of
plant collections possible, based on the eth-
nomedical approach in a given day or week,
becomes much smaller. 
In summary, the industrial approach most
likely to be used to evaluate plants for bioac-
tive compounds will be based on random col-
lection followed by automated, robotized, in
vitro screening. The ethnomedical approach
lends itself more to being carried out in acad-
emic institutions. Since plant-derived drug
discovery efforts began, the ethnomedical
approach has been more successful. However,
the random collection of plants, which pro-
vides the highest biodiversity, is forging ahead
as the method of choice. The latter approach
requires signiﬁcantly more ﬁnancial resources
than the former.
Conclusions and Perspectives
The body of existing ethnomedical knowl-
edge has led to great developments in health
care. With the rapid industrialization of the
planet and the loss of ethnic cultures and cus-
toms, some of this information will no doubt
disappear. An abundance of ethnomedical
information on plant uses can be found in the
scientiﬁc literature but has not yet been com-
piled into a usable form. Collection of eth-
nomedical information remains primarily an
academic endeavor of little interest to most
industrial groups. 
The use of ethnomedical information has
contributed to health care worldwide, even
though efforts to use it have been sporadic.
Are we loath to continue plant-derived drug
discovery efforts because we anticipate that
current industrial technology, i.e., mass
screening, will provide novel drugs at a greater
rate than will the ethnomedical information
already at hand? “Those who cannot remem-
ber the past are condemned to repeat it” (98).
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